Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDI Calidi Biotherapeutics	$5.01 -13.0%	$5.43	$2.43 ▼ $46.68	$15.16M	1.15	655,731 shs	164,927 shs
DRUG Bright Minds Biosciences	$38.82 +11.6%	$28.86	$0.94 ▼ $79.02	$273.45M	-6.07	40,092 shs	164,381 shs
IMA ImageneBio	$14.67 -0.2%	$16.15	$11.65 ▼ $23.28	$58.97M	0.51	48,362 shs	5,894 shs
MNPR Monopar Therapeutics	$34.65 -13.6%	$38.03	$1.72 ▼ $54.30	$211.89M	1.05	30,778 shs	28,909 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDI Calidi Biotherapeutics	0.00%	-29.27%	-58.17%	-9.02%	-74.23%
DRUG Bright Minds Biosciences	0.00%	+15.43%	+49.71%	+21.16%	+3,494.44%
IMA ImageneBio	0.00%	-15.10%	-12.05%	+7.71%	-25.00%
MNPR Monopar Therapeutics	0.00%	-14.84%	-9.44%	-12.63%	+1,094.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDI Calidi Biotherapeutics	0.231 of 5 stars	0.0	2.0	1.9	0.0	0.6
DRUG Bright Minds Biosciences	2.4098 of 5 stars	3.6	2.0	2.7	2.5	0.0
IMA ImageneBio	3.4683 of 5 stars	3.3	3.0	3.4	3.3	1.3
MNPR Monopar Therapeutics	1.941 of 5 stars	3.4	3.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDI Calidi Biotherapeutics	0.00	N/A	N/A	N/A
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	114.45% Upside
IMA ImageneBio	2.50	Moderate Buy	$35.50	141.99% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	73.16% Upside

Current Analyst Ratings Breakdown

Latest IMA, DRUG, CLDI, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/25/2025	IMA ImageneBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$25.00 ➝ $23.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	($2.32) per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
IMA ImageneBio	$9.16M	6.44	N/A	N/A	$28.83 per share	0.51
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
IMA ImageneBio	-$49.23M	-$7.68	N/A	N/A	N/A	N/A	-23.94%	-21.62%	8/14/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	N/A

Latest IMA, DRUG, CLDI, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IMA ImageneBio	-$0.14	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q3 2025	DRUG Bright Minds Biosciences	-$0.59	N/A	N/A	N/A	N/A	N/A
7/24/2025	Q2 2025	IMA ImageneBio	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
DRUG Bright Minds Biosciences	N/A	126.01	126.01
IMA ImageneBio	N/A	13.52	13.52
MNPR Monopar Therapeutics	N/A	36.91	36.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDI Calidi Biotherapeutics	12.53%
DRUG Bright Minds Biosciences	40.52%
IMA ImageneBio	75.00%
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
CLDI Calidi Biotherapeutics	6.70%
DRUG Bright Minds Biosciences	42.66%
IMA ImageneBio	5.94%
MNPR Monopar Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDI Calidi Biotherapeutics	38	3.03 million	20.04 million	N/A
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
IMA ImageneBio	70	4.02 million	3.78 million	Not Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable

IMA, DRUG, CLDI, and MNPR Headlines

Recent News About These Companies

Monopar Therapeutics (MNPR) Projected to Post Earnings on Friday

August 1, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Moderate Buy" from Analysts

July 18, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Sells $356,160.00 in Stock

July 17, 2025 | marketbeat.com

Christopher M. Starr Sells 16,800 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

July 17, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) CEO Sells $672,000.00 in Stock

July 17, 2025 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim R. Tsuchimoto Sells 8,904 Shares

July 17, 2025 | insidertrades.com

Cantor Fitzgerald Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation

July 8, 2025 | msn.com

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

June 26, 2025 | finance.yahoo.com

Institutional investors own a significant stake of 29% in Monopar Therapeutics Inc. (NASDAQ:MNPR)

June 23, 2025 | finance.yahoo.com

Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation

June 23, 2025 | msn.com

Monopar Therapeutics Inc.: Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | finanznachrichten.de

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

June 11, 2025 | zacks.com

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

June 11, 2025 | globenewswire.com

Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%

June 3, 2025 | msn.com

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

June 3, 2025 | globenewswire.com

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 14, 2025 | manilatimes.netM

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025 | globenewswire.com

Monopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025

May 8, 2025 | nasdaq.com

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025 | globenewswire.com

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025

April 30, 2025 | insidermonkey.com

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

April 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

5 Stocks to Buy and Hold for the Rise of Physical AI
By Thomas Hughes | July 23, 2025
View 5 Stocks to Buy and Hold for the Rise of Physical AI
This Fund Manager Says You Should Get Out of Tesla and Apple—Now
By Brian O'Connell | July 16, 2025
View This Fund Manager Says You Should Get Out of Tesla and Apple—Now
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
By Jordan Chussler | August 9, 2025
View Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
By Leo Miller | August 8, 2025
View Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down
By Leo Miller | August 7, 2025
View AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down

IMA, DRUG, CLDI, and MNPR Company Descriptions

Calidi Biotherapeutics NYSE:CLDI

$5.01 -0.75 (-13.02%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$5.15 +0.14 (+2.79%)

As of 08/8/2025 07:59 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Bright Minds Biosciences NASDAQ:DRUG

$38.82 +4.02 (+11.55%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$39.35 +0.53 (+1.37%)

As of 08/8/2025 05:23 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

ImageneBio NASDAQ:IMA

$14.67 -0.03 (-0.20%)

As of 08/8/2025 04:00 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Monopar Therapeutics NASDAQ:MNPR

$34.65 -5.45 (-13.59%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$39.25 +4.60 (+13.28%)

As of 08/8/2025 04:35 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time